(RTTNews) - Amneal Pharmaceuticals, Inc. (AMRX), an integrated essential medicines company, announced Wednesday that it has received Abbreviated New Drug Application or ANDA approval from the U.S.

New Delhi, Nov 14 (PTI) Zydus Lifesciences Ltd on Friday said it has received final approval from the US health regulator for its generic version of Leuprolide Acetate injection used in palliative ...

Mumbai, Nov. 14 -- Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) for Leuprolide Acetate injection, 14 mg/2.8 mL (1 mg/0.2 mL) multiple-dose ...

CS21 was a three-arm, randomized (1:1:1), open-label, parallel-group Phase III trial of 12 months' duration incorporating adult male patients with histologically confirmed adenocarcinoma of the ...

A head-to-head study comparing two types of androgen-deprivation therapy (ADT) for the treatment of prostate cancer showed there was no difference in the risk of major adverse cardiovascular events ...

Injectable luteinizing hormone–releasing hormone agonists (e.g., leuprolide) are the standard agents for achieving androgen deprivation for prostate cancer despite the initial testosterone surge and ...

The probability of survival at 8 years was an unprecedented 78.9% with XTANDI plus leuprolide versus 69.5% with leuprolide, in men with non-metastatic hormone-sensitive prostate cancer with high-risk ...

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the ...